Trial Profile
Single-Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Apixaban in Subjects on Hemodialysis.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Apixaban (Primary)
- Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 31 Aug 2015 Results published in the Journal of Clinical Pharmacology.
- 17 Oct 2011 Actual end date (Sep 2011) added as reported by ClinicalTrials.gov.
- 17 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.